FDA Approves Mavyret, a Pan-Genotypic Treatment for HCV

Press/Media: Press / Media

PeriodAug 1 2017 → Aug 3 2017

Media coverage

2

Media coverage

  • TitleFDA Approves Mavyret, a Pan-Genotypic Treatment for HCV
    Media name/outletMonthly Prescribing Reference
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleFDA Approves Mavyret, a Pan-Genotypic Treatment for HCV
    Media name/outletMonthly Prescribing Reference (MPR)
    CountryUnited States
    Date8/1/17
    PersonsFred Poordad